12:13

Digital integration for external manufacturing: A structure for conversation between partners

00:55

PAT monitoring and control roadmap animation

02:45

Digital integration for external manufacturing: A structure for conversation between partners

38:32

Environmental monitoring performance qualification

19:00

Part 3/3 - Navigating the cell and gene therapy supply chain insights, practices and distinctions

44:30

Part 2/3 - Navigating the cell and gene therapy supply chain insights, practices and distinctions

00:57

Shifting to water stewardship in the biopharmaceutical sector

01:01:37

Part 1/3 - Navigating the cell and gene therapy supply chain insights, practices and distinctions

01:09:59

BioPhorum Drug Substance introduces workstreams: Annex 1, Closed Systems and Microbial Control

58:41

Recycling plastics in biopharmaceutical manufacturing: What if we could close the loop?

01:05

What makes BioPhorum unique

01:25

Benefits of BioPhorum

01:08

What is BioPhorum

02:29

Host cell protein data platform demo

01:22

Host cell protein data platform introduction

55:01

BioPhorum Drug Substance introduces workstreams: Cell Banks, LIVCA and Multi Product Facility

01:00:01

PSCI x BioPhorum embedding water risk webinar

56:04

Leveraging platform & process characterization data to accelerate CGT validation & commercialization

01:29:14

Digital certificates of analysis & other transfers of quality test result data between organizations

02:35

Cell and gene therapy outbound supply chain pathway tool

26:05

Developing a harmonized approach to product carbon footprint data for the biopharma industry

39:39

Industry approaches and control strategy to implement ready-to-use cells in bioassays

42:42

Industry perspective of forced degradation studies to assess comparability of biopharmaceuticals

57:13

Overcoming big data challenges in biomanufacturing using ontology and digital data capture

01:59

Manufacturing execution systems (MES) integration for enhanced biopharmaceutical manufacturing

20:59

Guidance for risk evaluation of X-ray irradiation of single-use systems

50:55

BioPhorum digital plant maturity model (DPMM) 3.0 introduction

53:18

Advancing plug and play automation for biopharma processes (Part 2/2)

32:39

Strategies for minimizing the impact of stability testing on gene therapy batch yield

27:15

Bioreactivity testing in single-use system biomanufacturing

56:43

Advancing plug and play automation for biopharma processes (Part 1/2)

35:24

Business resilience in the biopharmaceutical industry

31:30

Current methods and factors to take into account for viral clearance in cell and gene therapy

59:51

Current practices and considerations of cell and gene therapy method validation controls

01:43:58

Standardizing traceability of personalized cell and gene therapies

53:46

Validating and implementing nucleic acid testing-based methods for mycoplasma detection

45:47

Implementing smart maintenance solutions in biopharmaceutical manufacturing

59:38

Vision for digital integration of sponsor and contract organizations

51:39

Rapid sterility test systems in the pharmaceutical industry

02:22:47

Med tech challenges for advanced wound care and wound management

01:03:13

Data governance needs in biomanufacturing

00:59

MediPhorum: Connecting MedTech industry experts

32:08

Transforming Regulatory CMC: from divergence to convergence

05:18

Welcome to The Hub

02:54

Introducing the BioPhorum environmental sustainability roadmap

40:09

Analyzing high concentration biologic therapeutic formulations

36:04

Supporting particle investigations with risk-based decision-making

25:05

Bio-fluorescent particle counting systems implementation challenges

26:54

Virtual twins for biomanufacturing

00:59

An introduction to the BioPhorum Hub

53:53

Implementing automated colony counting systems

17:07

Raw materials strategic framework

31:36

Protocolos de gestión de modificaciones posteriores a la aprobación en América Latina

23:57

Small scale model justification: An industry position paper

36:13

An intercompany perspective on compatibility and in-use stability studies

47:55

User stories for IT to support cell and gene therapy

30:27

Cell and gene therapy orchestration and exception management case study

01:03:21

Applying a matrix approach for potency assay development for in vivo and ex vivo gene therapies

56:33

Cell and gene therapy validation challenges

40:46

Digital technology-based capabilities for the QC lab of the future